ISB News

3-Minute Science: ISB and Seattle BioMed Hold Annual Lightning Talks

ISB and Seattle BioMed held its annual Lightning Talks on June 12, 2014. The talks offer scientists the chance to share current research and to enable potential collaborations across institutes.

Photo: Theo Knijnenburg, a research scientist in ISB's Shmulevich Lab, presentaed a summary of his work related to gene mutations and cancer drug sensitivity.

Systems biology is about the culture as much as a scientific approach. ISB and Seattle BioMed have an inter-institutional agreement that enables the collective to benefit from shared knowledge and technology resources. For the second consecutive year, we held Lightning Talks (June 12) to allow researchers from both organizations to present three-minute talks describing their current projects and needs that could benefit from input or collaboration. There also was a subsequent poster session and social hour.

 

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.